SiNtx Technologies, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Eric Kenneth Olson
- Full Time Employees
- 32
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1885 West 2100 South Salt Lake City UT United States 84119
- IPO Date
- Feb 13, 2014
- CIK
- 0001269026
- Website
- sintx.com
- Similar Companies
- Business
- SINTX Technologies, Inc. specializes in advanced ceramic materials with a particular focus on silicon nitride (Si3N4) for medical device applications. The company's primary products include silicon nitride spinal interbody fusion devices; orthopedic and reconstructive foot and ankle surgical implants such as the recently FDA 510(k) cleared SINAPTIC Foot & Ankle Osteotomy Wedge System; biologic products including the private-labeled OsseoSculpt™ for bone regeneration; and silicon nitride powders and composites used in medical implants and industrial applications. SINTX's product portfolio extends to custom silicon nitride ceramics for medical, dental, aerospace, defense, oil and gas, and automotive sectors, emphasizing high strength, biocompatibility, antibacterial properties, and resistance to wear and corrosion. The company supports its customers with design, engineering, prototyping, and testing services. Headquartered in Salt Lake City, Utah, SINTX advises a global market and benefits from ISO 13485:2016 and AS9100D certified manufacturing facilities. In the last two years, SINTX has undergone a significant strategic transformation marked by its acquisition of SiNAPTIC Surgical, a silicon nitride orthopedic and spine implant innovator, expanding its portfolio and adding FDA-cleared interbody spinal implants and foot and ankle fusion wedges. The company has divested non-core assets including the sale of its Maryland subsidiary Technology Assessment & Transfer, Inc. in early 2025 and ceased its armor ceramics facility operations in 2024, focusing exclusively on high-margin medical device markets. In 2025, SINTX received FDA 510(k) clearance for its SINAPTIC Foot & Ankle Osteotomy Wedge System and recorded its first commercial revenue from OsseoSculpt orders. It has also published research demonstrating powerful antiviral properties of its silicon nitride material against SARS-CoV-2 and MERS-CoV, positioning itself for licensing and co-development opportunities in wound dressings, implant coatings, and filtration media. The company has restructured leadership, emphasizing commercialization and innovation in the orthopedic and surgical segments. Founded in 2002, SINTX Technologies operates primarily in the biomedical ceramics industry, targeting medical device manufacturers, healthcare providers, and specialty implant customers. Its strategic focus is on silicon nitride biomaterials for spinal surgery, dental implants, and orthopedic reconstruction, leveraging proprietary patented technology and manufacturing expertise. The company's strategic realignment towards medical applications and divestiture of less profitable OEM manufacturing segments demonstrate a clear commitment to growing its medical device business globally. SINTX Technologies is publicly traded under the ticker SINT on NASDAQ and continues to expand its commercial and R&D operations to drive growth in silicon nitride-based medical devices and biomaterials solutions.
Company News
SINTX Technologies Announces Third Quarter 2026 Earnings Release Date and Webcast
What Makes SINTX TECHNOLOGIES (SINT) a New Buy Stock
SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance
Avanos Medical (NYSE:AVNS) and Sintx Technologies (NASDAQ:SINT) Financial Analysis
Reviewing Cooper Companies (NASDAQ:COO) and Sintx Technologies (NASDAQ:SINT)
SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts
SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade
SINTX Technologies Regains Compliance with Nasdaq Stockholders' Equity Requirement
Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call Prepared Remarks Transcript
SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives
SINTX Technologies Announces Second Quarter 2026 Earnings Release Date and Webcast
SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program
SINTX Technologies Announces Receipt of More Than $3.2 Million in Contract Manufacturing Purchase Orders
SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SINTX Technologies to Present at the LD Micro Invitational XVI Conference
Sintx Technologies (NASDAQ:SINT) versus Vasamed (OTCMKTS:VSMD) Critical Review
SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution
SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant
Critical Analysis: OPKO Health (NASDAQ:OPK) vs. Sintx Technologies (NASDAQ:SINT)